Ionis Pharmaceuticals(IONS) - 2025 Q3 - Quarterly Results
Ionis Pharmaceuticals(US:IONS)2025-10-29 11:06- TRYNGOLZA® generated $32 million in net product sales in the third quarter 2025 - - DAWNZERA™ (donidalorsen) launch of to encouraging start - - Olezarsen significantly reduced triglycerides and acute pancreatitis events in severe hypertriglyceridemia (sHTG) in landmark Phase 3 studies; sNDA submission on track by year-end – - Positive pivotal zilganersen results in Alexander disease position Ionis for first independent neurology launch in 2026 - Exhibit 99.1 Ionis reports third quarter 2025 financial resu ...